Tallac Therapeutics

Total Funding
$182.0M
Last Round
$120.0M Series BMay 2024
Rounds
2

About

Biopharmaceutical company developing CpG-Antibody conjugates for cancer immunotherapy

Summary

It has raised $182.0M in total across 2 rounds, most recently a $120.0M Series B round in May 2024. Investors include TCGX, Horizon Technology Finance and venBIO Partners.

Sign up to view the funding chart

Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.

Funding History

Series BSeries BMay 2024
$120.0M

Sign up to see all 3 rounds

Full funding history, per-round amounts, and investor participation.

Investors